liposic 2 mg/g eye gel
bausch + lomb ireland limited - carbomer - eye gel - other ophthalmologicals; artificial tears and other indifferent preparations
liposic
bausch & lomb uk limited - carbomer - eyegel - 2 mg/g - artificial tears and other indifferent preparations
yellox
bausch + lomb ireland limited - bromfenac sodium sesquihydrate - pain, postoperative; ophthalmologic surgical procedures - ophthalmologicals - treatment of postoperative ocular inflammation following cataract extraction in adults.
lipolin 2mg/g sterile ophthalmic gel
bausch & lomb philippines, inc.; distributor: bausch & lomb philippines, inc. - carbomer - sterile ophthalmic gel - 2mg/g
dr reddy's irbesartan
dr reddy's laboratories australia pty ltd - irbesartan -
dr reddy's omeprazole 10mg
dr reddy's new zealand limited - omeprazole 10mg; - modified release capsule - 10 mg - active: omeprazole 10mg excipient: capsugel purple op.c046 capsugel yellow op.c305 crospovidone hypromellose isopropyl alcohol magnesium stearate mannitol meglumine methacrylic acid - ethyl acrylate copolymer opacode black s-1-27794 poloxamer povidone purified water triethyl citrate
dr reddy's sertraline
dr reddy's new zealand limited - sertraline hydrochloride 111.92mg equivalent to sertraline 100 mg - film coated tablet - 100 mg - active: sertraline hydrochloride 111.92mg equivalent to sertraline 100 mg excipient: calcium hydrogen phosphate colloidal silicon dioxide hyprolose magnesium stearate microcrystalline cellulose opadry white oy-58900 polysorbate 80 sodium starch glycolate - sertraline is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.
dr reddy's sertraline
dr reddy's new zealand limited - sertraline hydrochloride 55.96mg equivalent to sertraline 50 mg - film coated tablet - 50 mg - active: sertraline hydrochloride 55.96mg equivalent to sertraline 50 mg excipient: calcium hydrogen phosphate colloidal silicon dioxide hyprolose magnesium stearate microcrystalline cellulose opadry white oy-58900 polysorbate 80 sodium starch glycolate - sertraline is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.
bosentan dr.reddy's bosentan (as monohydrate) 125 mg tablet blister pack
dr reddys laboratories australia pty ltd - bosentan monohydrate, quantity: 129.082 mg - tablet, film coated - excipient ingredients: maize starch; pregelatinised maize starch; sodium starch glycollate type a; povidone; glycerol dibehenate; magnesium stearate; hypromellose; titanium dioxide; triacetin; purified talc; iron oxide yellow; iron oxide red; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms
bosentan dr.reddy's bosentan (as monohydrate) 62.5 mg tablet blister pack
dr reddys laboratories australia pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: maize starch; pregelatinised maize starch; sodium starch glycollate type a; povidone; glycerol dibehenate; magnesium stearate; hypromellose; titanium dioxide; triacetin; purified talc; iron oxide yellow; iron oxide red; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms